baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

AnaptysBio Inc/ US0327241065 /

2024-04-15 10:00:00 PM	Chg. -1.4400	Volume	Bid1:59:47 PM	Ask1:59:47 PM	High	Low
21.2700USD	-6.34%	267,275 Turnover: 4.31 mill.	21.6500Bid Size: 600	23.9800Ask Size: 100	23.1000	21.0600

GlobeNewswire 03-26 Attovia Enhances Clinical and Development Expertise with Appointment of Chief Medical Officer and Cl...

GlobeNewswire 03-11 Anaptys Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

GlobeNewswire 02-29 Anaptys to Present at TD Cowen’s 44th Annual Health Care Conference and 2024 AAD Annual Meeting

GlobeNewswire 01-31 Anaptys to Present at Guggenheim’s 6th Annual Biotechnology Conference

GlobeNewswire 2023-11-27 Anaptys Expands Immune Cell Modulator Pipeline with Exclusive License to BDCA2 Modulator Antibody Po...

GlobeNewswire 2023-11-11 SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of AnaptysBio, Inc. (NASDAQ: ANAB) and En...

GlobeNewswire 2023-11-07 Anaptys Named a BioSpace 2024 Best Places to Work Winner

GlobeNewswire 2023-11-07 INVESTOR ALERT: Abbott Cooper PLLC Announces Investigation into AnaptysBio, Inc.; Urges AnaptysBio’s...

GlobeNewswire 2023-11-02 Anaptys Announces Third Quarter 2023 Financial Results and Provides Business Update

GlobeNewswire 2023-11-01 Anaptys Announces Participation in November Investor Conferences

GlobeNewswire 2023-10-11 Anaptys to Present Phase 1 Data on ANB032, its BTLA Agonist Antibody, at the 32nd EADV Congress

GlobeNewswire 2023-10-09 Anaptys to Provide Overview of Rosnilimab, a PD-1 Agonist, at Virtual R&D Event on Wednesday, Oct. 2...

GlobeNewswire 2023-10-09 Anaptys Announces Positive Top-Line Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Genera...

GlobeNewswire 2023-09-18 AnaptysBio Announces Appointment of John Orwin as Chairman of the Board of Directors

GlobeNewswire 2023-09-12 AnaptysBio to Present at the Stifel 2023 Immunology and Inflammation Virtual Summit

GlobeNewswire 2022-03-21 AnaptysBio Appoints Daniel Faga As Interim Chief Executive Officer

GlobeNewswire 2022-03-14 AnaptysBio Reports Imsidolimab ACORN Phase 2 Clinical Trial Data in Moderate-to-Severe Acne

GlobeNewswire 2022-03-07 AnaptysBio Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Pipeline Updat...

GlobeNewswire 2022-01-06 Recludix Pharma Announces Scientific Advisory Board

GlobeNewswire 2022-01-05 AnaptysBio To Present at the 40th Annual J.P. Morgan Healthcare Conference

GlobeNewswire 2021-11-29 AnaptysBio Announces Appointment of Daniel Faga to Board of Directors

GlobeNewswire 2021-11-16 AnaptysBio To Present at the 2021 Jefferies London Healthcare Conference

GlobeNewswire 2021-11-15 AnaptysBio Announces Positive Rosnilimab Healthy Volunteer Phase 1 Top-Line Data

GlobeNewswire 2021-11-15 Recludix Pharma Launches with $60 Million Series A to Support Innovative Platform to Discover and De...

GlobeNewswire 2021-11-04 AnaptysBio Announces Third Quarter 2021 Financial Results and Provides Pipeline Updates

AnaptysBio Inc/ US0327241065 /

If you wish to receive reply to your feedback, please provide your email address.